Wells Fargo lowered the firm’s price target on Zentalis (ZNTL) to $5 from $6 and keeps an Equal Weight rating on the shares. The firm says it remains on the sidelines due to Zentalis’ lack of catalysts as azeno’s DENALI Part 2a/b top line data in CCNE1+ PROC won’t be reported until year-end 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism
- Zentalis Pharmaceuticals Reports Improved Financial Results
- Zentalis Pharmaceuticals Reports Q2 2025 Financial Results
- Zentalis management to meet with Oppenheimer
- Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting